Search results
Results from the WOW.Com Content Network
In October 2020, Hims closed a deal with Oaktree Capital Management to go public through a blank check company, reaching a valuation of $1.6 billion. [7] As part of the deal, the company was renamed Hims & Hers Health Inc. [11] The transaction was completed in January 2021, and the company started trading publicly on the New York Stock Exchange.
Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.
The Better Business Bureau (BBB) is an American private, 501(c)(6) nonprofit organization founded in 1912. BBB's self-described mission is to focus on advancing marketplace trust, [2] consisting of 92 independently incorporated local BBB organizations in the United States and Canada, coordinated under the International Association of Better Business Bureaus (IABBB) in Arlington, Virginia.
Hims & Hers is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded GLP-1s on the market.The tracker allows patients to self-identify, provide ...
Hims & Hers announced earnings Monday and upgraded revenue guidance by $20 million, to $830 to $850 million for the year — and provided guidance that it will launch its weight loss management ...
The company pivoted transforming its technology into a new product to measure bad breath and oral health, called Mint. [22] Breathometer released the Mint in September 2016. Sensors in the device measured sulfur compounds associated with bad breath and that scientists associate with periodontitis aka gum disease. [ 23 ]
Breath Savers have also begun advertising some of their mints to contain sodium bicarbonate, an alkaline salt used in many personal hygiene products as a mechanical cleanser on the teeth and gums. It also neutralizes the production of acid in the mouth, and acts as an antiseptic to help prevent infections.
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.